

Suven Discovery Scientific Presentations in 2010

ACS Meeting & Exposition August 22 - 26, 2010, Boston, MA, USA

1. New aryl sulfonamide compounds as potent and selective 5-HT₆ receptor ligands.
A. Shinde, et al.,
2. Amino aryl sulfonamides as novel and potent 5-HT₆ receptor ligands.
R. Nirogi, et al.,

37th Annual Meeting & Exposition of the Controlled Release Society (CRS) July 10 – 14, 2010, Portland, OR, USA

3. Effect of Fillers on the Release Profile of Monolithic Dosage Formulation with HPMC as a Matrix.
K. Kurapati et al.,
4. Influence of Method of Hydrophilic Polymer Addition on Drug Release from Matrix Tablets.
R. Manthri et al.,

International Conference on Alzheimer's Disease (ICAD) July 11 - 15, 2010, Honolulu, Hawaii, USA

5. SUVN-91052: A potent and selective 5-HT₄ agonist for the treatment of Alzheimer's disease.
I. Ahmad, et. al.,
6. The novel and selective α 4 β 2 agonist, SUVN-911 enhances acetylcholine levels in frontoparietal cortex.
G. Bhyrapuneni, et. al.,
7. SUVN-90121: A selective nicotinic acetylcholine receptor (nAChR) ligand for the treatment of cognitive impairment and depression.
P. Jayarajan, et. al.,
8. SUVN-91121: A novel and selective H3 antagonist for the improvement of memory related disorders.
V. Kandikere, et. al.,



**Society of Neuroscience (SFN)
November 13-17, 2010, San Diego, CA, USA**

9. *In-vivo* receptor occupancy for neuronal nicotinic acetylcholine $\alpha 4\beta 2$ receptors in rats using unlabelled ZW-104 as tracer
K. Mudigonda, et. al.,
10. Preclinical investigations into the neurochemical profile of SUVN-G1031, a novel histamine H3 receptor antagonist
V. Kandikere, et. al.,
11. Procognitive properties of SUVN-G1031, a novel selective H3 receptor antagonist in rat models of cognitive deficits
D. Shanmuganathan, et. al.,
12. SUVN-F91201: A potent and selective nicotinic acetylcholine $\alpha 4\beta 2$ receptor agonist for the treatment of Alzheimer's disease
P. Jayarajan, et. al.,
13. SUVN-911: A potent and selective nicotinic acetylcholine $\alpha 4\beta 2$ receptor antagonist for the treatment of depression and other mood disorders
R. V. Nirogi, et. al.,
14. SUVN-911: Pharmacological and safety profile of a novel and selective nicotinic acetylcholine $\alpha 4\beta 2$ receptor antagonist for the treatment of depression and other mood disorders
G. Bhyrapuneni, et. al.,
15. Effects of SUVN-F90101, a neuronal nicotinic acetylcholine receptors agonist in animal models of neuropathic pain
I. Ahmad, et. al.,
16. SUVN-D1003019: A selective 5-HT₄ receptor agonist for the treatment of Alzheimer's disease
R. Abraham, et. al.,
17. *In-vivo* brain microdialysis to study drug interaction of neuroactive compounds
N. Muddana, et. al.,

**FIP Pharmaceutical Sciences World Congress in association with AAPS
November 14-18, 2010, New Orleans, LU, USA**

18. Effect of fillers on the release profile of monolithic dosage formulation with HPMC as a matrix.
D. Dogiparti, et. al.,
19. Simultaneous measurement of tele-methyl histamine and histamine levels in rat brain regions and CSF using LC-HILIC-MS/MS
R. Poonnamaneni, et. al.,

20. *In-vivo* histamine H3 antagonist receptor occupancy assay in rats using non-radioactive tracer.
R. Saralaya, et. al.,
21. Swift Development of Preclinical Formulations for Pharmacokinetic, Efficacy and Toxicology Studies in Drug Discovery.
K. Mudigonda, et. al.,
22. Exploring *in-vivo* brain microdialysis in rats to evaluate drug drug interaction of neuroactives.
V. Benade, et. al.,
23. Effects of selected histamine H3 receptor antagonists on tele-methylhistamine levels in rat.
N. Muddana, et. al.,
24. Investigation of the Effect of Different Initial Drug Loading on Drug Release from Fixed Weight Hydrophilic Matrices.
K. Kishore, et. al.,